• HighLife raised more than USD 90 million (EUR 80 million) in a private financing round co-led by Andera Partners.
• HighLife is a medtech company developing transcatheter solutions for structural heart disease, focused on transcatheter mitral valve replacement.
• Proceeds target European commercial expansion, execution of a US pivotal clinical study, strengthening the organization for longer-term growth.
• HighLife’s TMVR system received CE Mark clearance in January; its next-generation Clarity Valve received CE Mark clearance in July.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Andera Partners SAS published the original content used to generate this news brief on September 22, 2026, and is solely responsible for the information contained therein.